TABLE 1

Univariate analysis of clinicopathological variables, T-lymphocyte markers and survival

SubjectsHazard ratio (95% CI)p-value
Age years
 <65931
 ≥65931.365 (0.927–2.008)0.115
Sex
 Male1151
 Female710.378
Smoking status
 Current and ex-smokers1751
 Never-smokers111.46 (0.677–3.151)0.334
Type of surgery0.865
 Lobectomy1371
 Bilobectomy170.723 (0.442–1.761)0.883
 Pneumonectomy320.654 (0.525–1.499)0.887
Tumour size
 <5 cm1241
 ≥5 cm622.155 (1.456–3.189)<0.001
Tumour stage
 T1401
 T2 and T31461.671 (0.993–2.810)0.053
Node stage
 N01141
 N1 and N2721.527 (1.037–2.249)0.032
WHO overall pathological stage0.002
 IA and IB1031
 IIA and IIB441.358 (0.837–2.203)0.215
 IIIA392.296 (1.458–3.614)0.000
Tumour grade0.699
 1131
 21100.745 (0.369–1.504)0.411
 3630.808 (0.389–1.679)0.567
Histological subtype0.868
 Squamous851
 Adenocarcinoma841.036 (0.691–1.552)0.865
 Large cell51.111 (0.346–3.574)0.859
 Mixed121.408 (0.635–3.122)0.400
Surgical resection margins
 Negative1631
 Positive232.259 (1.355–3.766)0.002
EGFR mutation
 Negative1751
 Positive110.71 (0.255–1.976)0.5
KRAS mutation
 Negative1751
 Positive111.36 (0.582–3.171)0.47
TI/S CD3+
 <Median861
 ≥Median880.703 (0.470–1.05)0.086
TI/S CD8+
 <Median881
 ≥Median910.440 (0.292–0.665)<0.001
TI/S Foxp3+
 <Median901
 ≥Median864.860 (3.112–7.588)<0.001
  • Data are presented as n, unless otherwise stated. WHO: World Health Organization; EGFR: epidermal growth factor receptor; KRAS: V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue; TI/S: tumour islet/stroma ratio; Foxp3: forkhead box P3.